Bristol-Myers Squibb Co Financials

BMY

Source SEC Filings (10-K/10-Q) Updated Feb 11, 2026 Currency USD FYE February

Financial Health Signals

Financial Profile 51/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Growth

Bristol-Myers Squibb Co's revenue declined 100% year-over-year, from $48.3B to $47K. This contraction results in a growth score of 0/100.

Leverage

Bristol-Myers Squibb Co has elevated debt relative to equity (D/E of 2.32), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 25/100, reflecting increased financial risk.

Liquidity

Bristol-Myers Squibb Co's current ratio of 1.26 indicates adequate short-term liquidity, earning a score of 30/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

100

Bristol-Myers Squibb Co converts 27.5% of revenue into free cash flow ($13K). This strong cash generation earns a score of 100/100.

Returns

100

Bristol-Myers Squibb Co earns a strong 38.2% return on equity (ROE), meaning it generates $38 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 100/100.

Piotroski F-Score Neutral

6/9

Bristol-Myers Squibb Co passes 6 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Cash-Backed

2.01x

For every $1 of reported earnings, Bristol-Myers Squibb Co generates $2.01 in operating cash flow ($14K OCF vs $7K net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

This page shows Bristol-Myers Squibb Co (BMY) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 19 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Export CSV

Key Financial Metrics

Revenue

$47K

YoY-100.0%

5Y CAGR-93.6%

10Y CAGR-72.1%

Bristol-Myers Squibb Co generated $47K in revenue in fiscal year 2025. This represents a decrease of 100.0% from the prior year.

EBITDA

N/A

Free Cash Flow

$13K

YoY-100.0%

5Y CAGR-93.7%

10Y CAGR-68.4%

Bristol-Myers Squibb Co generated $13K in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 100.0% from the prior year.

Net Income

$7K

YoY+100.0%

10Y CAGR-70.8%

Bristol-Myers Squibb Co reported $7K in net income in fiscal year 2025. This represents an increase of 100.0% from the prior year.

EPS (Diluted)

$3.46

YoY+178.5%

10Y CAGR+14.0%

Bristol-Myers Squibb Co earned $3.46 per diluted share (EPS) in fiscal year 2025. This represents an increase of 178.5% from the prior year.

Cash & Debt

$10K

YoY-100.0%

5Y CAGR-94.1%

10Y CAGR-70.9%

Bristol-Myers Squibb Co held $10K in cash against $43K in long-term debt as of fiscal year 2025.

Dividends Per Share

$2.49

YoY+2.9%

5Y CAGR+6.2%

10Y CAGR+5.3%

Bristol-Myers Squibb Co paid $2.49 per share in dividends in fiscal year 2025. This represents an increase of 2.9% from the prior year.

Shares Outstanding

2.04B

YoY+0.4%

5Y CAGR-1.9%

10Y CAGR+2.0%

Bristol-Myers Squibb Co had 2.04B shares outstanding in fiscal year 2025. This represents an increase of 0.4% from the prior year.

Gross Margin

70.2%

YoY-0.9pp

5Y CAGR-2.1pp

10Y CAGR-6.2pp

Bristol-Myers Squibb Co's gross margin was 70.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 0.9 percentage points from the prior year.

Operating Margin

N/A

Net Margin

15.1%

YoY+33.6pp

5Y CAGR+36.3pp

10Y CAGR+5.6pp

Bristol-Myers Squibb Co's net profit margin was 15.1% in fiscal year 2025, showing the share of revenue converted to profit. This is up 33.6 percentage points from the prior year.

Return on Equity

38.2%

10Y CAGR+27.2pp

Bristol-Myers Squibb Co's ROE was 38.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.

R&D Spending

$10K

YoY-100.0%

5Y CAGR-93.7%

10Y CAGR-73.5%

Bristol-Myers Squibb Co invested $10K in research and development in fiscal year 2025. This represents a decrease of 100.0% from the prior year.

Share Buybacks

$5K

5Y CAGR-92.0%

Bristol-Myers Squibb Co spent $5K on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Capital Expenditures

$1K

YoY-100.0%

5Y CAGR-93.0%

10Y CAGR-73.7%

Bristol-Myers Squibb Co invested $1K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 100.0% from the prior year.

BMY Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$47K-100.0%	$48.3B+7.3%	$45.0B-2.5%	$46.2B-0.5%	$46.4B+9.1%	$42.5B
Cost of Revenue	$14K-100.0%	$14.0B+30.6%	$10.7B+5.5%	$10.1B+2.0%	$9.9B-15.6%	$11.8B
Gross Profit	$33K-100.0%	$34.3B+0.1%	$34.3B-4.7%	$36.0B-1.2%	$36.4B+18.5%	$30.7B
R&D Expenses	$10K-100.0%	$11.2B+20.0%	$9.3B-2.2%	$9.5B-6.7%	$10.2B+1.5%	$10.0B
SG&A Expenses	$7K-100.0%	$8.4B+8.3%	$7.8B-0.5%	$7.8B+1.6%	$7.7B+0.4%	$7.7B
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$2K-100.0%	$1.9B+67.0%	$1.2B-5.4%	$1.2B-7.6%	$1.3B-6.1%	$1.4B
Income Tax	$2K-100.0%	$554.0M+38.5%	$400.0M-70.8%	$1.4B+26.2%	$1.1B-49.0%	$2.1B
Net Income	$7K+100.0%	-$8.9B-211.5%	$8.0B+26.8%	$6.3B-9.5%	$7.0B+177.6%	-$9.0B
EPS (Diluted)	$3.46+178.5%	$-4.41-214.2%	$3.86+30.8%	$2.95-5.4%	$3.12+178.2%	$-3.99

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$12.5B+2.3%	$12.2B-0.4%	$12.3B+9.5%	$11.2B-9.2%	$12.3B+3.8%	$11.9B-2.5%	$12.2B+2.8%	$11.9B
Cost of Revenue	$4.1B+19.2%	$3.4B+1.9%	$3.4B+11.2%	$3.0B-37.0%	$4.8B+62.7%	$3.0B-9.5%	$3.3B+11.4%	$2.9B
Gross Profit	$8.4B-4.3%	$8.8B-1.2%	$8.9B+8.9%	$8.2B+8.5%	$7.5B-15.7%	$8.9B0.0%	$8.9B0.0%	$8.9B
R&D Expenses	$2.6B+2.3%	$2.5B-2.0%	$2.6B+14.3%	$2.3B-29.3%	$3.2B+34.4%	$2.4B-18.1%	$2.9B+7.6%	$2.7B
SG&A Expenses	$2.2B+21.9%	$1.8B+4.4%	$1.7B+8.1%	$1.6B-25.8%	$2.1B+7.7%	$2.0B+2.9%	$1.9B-18.5%	$2.4B
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$432.0M-10.0%	$480.0M-1.0%	$485.0M-1.8%	$494.0M-0.4%	$496.0M-1.8%	$505.0M-3.1%	$521.0M+22.6%	$425.0M
Income Tax	$384.0M-58.2%	$919.0M+99.8%	$460.0M-9.6%	$509.0M+414.1%	$99.0M-78.5%	$461.0M+215.8%	-$398.0M-201.5%	$392.0M
Net Income	$1.1B-50.6%	$2.2B+68.0%	$1.3B-46.7%	$2.5B+3311.1%	$72.0M-94.1%	$1.2B-27.9%	$1.7B+114.1%	-$11.9B
EPS (Diluted)	$0.54-50.0%	$1.08+68.8%	$0.64-46.7%	$1.20+2300.0%	$0.05-91.7%	$0.60-27.7%	$0.83+114.1%	$-5.89

BMY Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$90K-100.0%	$92.6B-2.7%	$95.2B-1.7%	$96.8B-11.4%	$109.3B-7.7%	$118.5B
Current Assets	$29K-100.0%	$29.8B-6.3%	$31.8B+16.5%	$27.3B-18.0%	$33.3B+10.2%	$30.2B
Cash & Equivalents	$10K-100.0%	$10.3B-9.8%	$11.5B+25.7%	$9.1B-34.7%	$14.0B-3.9%	$14.5B
Inventory	$3K-100.0%	$2.6B-3.9%	$2.7B+13.8%	$2.3B+11.6%	$2.1B+1.0%	$2.1B
Accounts Receivable	$10K-100.0%	$9.0B+1.5%	$8.9B+9.0%	$8.2B+2.2%	$8.0B+10.5%	$7.2B
Goodwill	$22K-100.0%	$21.7B+2.6%	$21.2B+0.1%	$21.1B+3.2%	$20.5B-0.2%	$20.5B
Total Liabilities	$72K-100.0%	$76.2B+16.1%	$65.7B0.0%	$65.7B-10.4%	$73.3B-9.0%	$80.6B
Current Liabilities	$23K-100.0%	$23.8B+6.8%	$22.3B+1.7%	$21.9B+0.1%	$21.9B+14.6%	$19.1B
Long-Term Debt	$43K-100.0%	$47.6B+29.9%	$36.7B+4.6%	$35.1B-11.5%	$39.6B-18.1%	$48.3B
Total Equity	$18K-100.0%	$16.3B-44.5%	$29.4B-5.3%	$31.1B-13.6%	$35.9B-5.0%	$37.8B
Retained Earnings	$17K-100.0%	$14.9B-48.2%	$28.8B+12.8%	$25.5B+7.1%	$23.8B+11.9%	$21.3B

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$90.0B-7.1%	$96.9B+2.3%	$94.7B+2.4%	$92.4B-0.2%	$92.6B-1.1%	$93.7B-1.0%	$94.6B-4.4%	$99.0B
Current Assets	$29.4B-17.5%	$35.6B+7.2%	$33.2B+7.9%	$30.8B+3.4%	$29.8B+6.1%	$28.1B+4.4%	$26.9B-6.2%	$28.7B
Cash & Equivalents	$10.2B-35.1%	$15.7B+24.8%	$12.6B+15.9%	$10.9B+5.1%	$10.3B+31.1%	$7.9B+25.4%	$6.3B-32.6%	$9.3B
Inventory	$2.7B-2.5%	$2.8B+0.8%	$2.7B+2.7%	$2.7B+4.3%	$2.6B-23.3%	$3.3B+8.3%	$3.1B+3.1%	$3.0B
Accounts Receivable	$9.6B-0.3%	$9.6B-0.9%	$9.7B+7.1%	$9.1B+0.6%	$9.0B-3.3%	$9.3B-4.4%	$9.7B+10.4%	$8.8B
Goodwill	$21.8B0.0%	$21.7B-0.1%	$21.8B+0.2%	$21.7B+0.1%	$21.7B-0.1%	$21.8B+0.1%	$21.7B0.0%	$21.7B
Total Liabilities	$71.5B-8.6%	$78.3B+1.4%	$77.2B+2.9%	$75.0B-1.6%	$76.2B-0.3%	$76.5B-1.4%	$77.6B-5.9%	$82.5B
Current Liabilities	$23.4B-16.8%	$28.1B+2.2%	$27.5B+14.4%	$24.1B+1.2%	$23.8B+5.0%	$22.6B-2.7%	$23.3B-9.9%	$25.8B
Long-Term Debt	$42.9B-3.6%	$44.5B0.0%	$44.5B-3.7%	$46.2B-3.0%	$47.6B-2.2%	$48.7B-0.4%	$48.9B-1.3%	$49.5B
Total Equity	$18.5B-0.4%	$18.6B+6.4%	$17.4B+0.3%	$17.4B+6.5%	$16.3B-4.7%	$17.1B+0.7%	$17.0B+3.2%	$16.5B
Retained Earnings	$16.9B-1.2%	$17.1B+5.8%	$16.2B+0.3%	$16.1B+8.0%	$14.9B-7.4%	$16.1B0.0%	$16.1B+3.0%	$15.6B

BMY Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$14K-100.0%	$15.2B+9.6%	$13.9B+6.1%	$13.1B-19.4%	$16.2B+15.3%	$14.1B
Capital Expenditures	$1K-100.0%	$1.2B+3.2%	$1.2B+8.1%	$1.1B+14.9%	$973.0M+29.2%	$753.0M
Free Cash Flow	$13K-100.0%	$13.9B+10.2%	$12.7B+5.9%	$11.9B-21.6%	$15.2B+14.5%	$13.3B
Investing Cash Flow	$4K+100.0%	-$21.4B-830.4%	-$2.3B-116.1%	-$1.1B-97.4%	-$538.0M+95.0%	-$10.9B
Financing Cash Flow	$10K-100.0%	$5.1B+154.4%	-$9.4B+44.5%	-$17.0B-4.5%	-$16.2B-1309.6%	-$1.2B
Dividends Paid	$5K-100.0%	$4.9B+2.5%	$4.7B+2.4%	$4.6B+5.4%	$4.4B+7.9%	$4.1B
Share Buybacks	$5K	$0-100.0%	$5.2B-35.6%	$8.0B+27.3%	$6.3B+306.7%	$1.5B

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$2.0B-68.7%	$6.3B+61.1%	$3.9B+100.5%	$2.0B-56.0%	$4.4B-20.6%	$5.6B+140.4%	$2.3B-17.9%	$2.8B
Capital Expenditures	$370.0M+15.6%	$320.0M-11.4%	$361.0M+38.8%	$260.0M-31.2%	$378.0M+16.7%	$324.0M+23.7%	$262.0M-7.7%	$284.0M
Free Cash Flow	$1.6B-73.2%	$6.0B+68.5%	$3.6B+109.9%	$1.7B-58.3%	$4.1B-22.9%	$5.3B+155.2%	$2.1B-19.1%	$2.5B
Investing Cash Flow	-$1.5B+14.3%	-$1.7B-259.8%	-$473.0M+5.2%	-$499.0M-154.6%	-$196.0M+10.5%	-$219.0M+83.4%	-$1.3B+93.3%	-$19.6B
Financing Cash Flow	-$6.0B-304.6%	-$1.5B+18.8%	-$1.8B-84.9%	-$993.0M+39.5%	-$1.6B+57.4%	-$3.9B+4.3%	-$4.0B-127.5%	$14.6B
Dividends Paid	$1.3B-0.1%	$1.3B+0.1%	$1.3B+0.3%	$1.3B+3.3%	$1.2B+0.2%	$1.2B-0.1%	$1.2B+0.4%	$1.2B
Share Buybacks	N/A	N/A	N/A	N/A	$0	$0	$0	$0

BMY Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	70.2%-0.9pp	71.1%-5.2pp	76.2%-1.8pp	78.0%-0.5pp	78.6%+6.3pp	72.3%
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	15.1%+33.6pp	-18.5%-36.4pp	17.8%+4.1pp	13.7%-1.4pp	15.1%+36.3pp	-21.2%
Return on Equity	38.2%	N/A	27.3%+6.9pp	20.4%+0.9pp	19.5%	N/A
Return on Assets	7.8%+17.5pp	-9.7%-18.1pp	8.4%+1.9pp	6.5%+0.1pp	6.4%+14.0pp	-7.6%
Current Ratio	1.260.0	1.25-0.2	1.43+0.2	1.25-0.3	1.52-0.1	1.58
Debt-to-Equity	2.32-0.6	2.91+1.7	1.25+0.1	1.13+0.0	1.10-0.2	1.28
FCF Margin	27.5%-1.4pp	28.9%+0.8pp	28.1%+2.2pp	25.9%-7.0pp	32.8%+1.6pp	31.3%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	67.2%-4.6pp	71.9%-0.6pp	72.5%-0.4pp	72.9%+11.9pp	61.0%-14.1pp	75.1%+1.9pp	73.2%-2.1pp	75.3%
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	8.7%-9.3pp	18.0%+7.3pp	10.7%-11.2pp	21.9%+21.3pp	0.6%-9.6pp	10.2%-3.6pp	13.8%+114.2pp	-100.4%
Return on Equity	5.9%-6.0pp	11.9%+4.3pp	7.5%-6.6pp	14.1%+13.7pp	0.4%-6.6pp	7.1%-2.8pp	9.9%	N/A
Return on Assets	1.2%-1.1pp	2.3%+0.9pp	1.4%-1.3pp	2.7%+2.6pp	0.1%-1.2pp	1.3%-0.5pp	1.8%+13.8pp	-12.0%
Current Ratio	1.26-0.0	1.27+0.1	1.21-0.1	1.28+0.0	1.25+0.0	1.24+0.1	1.16+0.0	1.11
Debt-to-Equity	2.32-0.1	2.40-0.2	2.55-0.1	2.65-0.3	2.91+0.1	2.84-0.0	2.87-0.1	3.00
FCF Margin	12.8%-36.2pp	49.0%+20.0pp	29.0%+13.9pp	15.1%-17.8pp	32.9%-11.4pp	44.3%+27.4pp	16.9%-4.6pp	21.5%

Similar Companies

$117.5B

$113.6B

$156.2B

$197.4B

Gilead Sciences Inc GILD

$188.4B

Frequently Asked Questions

What is Bristol-Myers Squibb Co's annual revenue?

Bristol-Myers Squibb Co (BMY) reported $47K in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Bristol-Myers Squibb Co's revenue growing?

Bristol-Myers Squibb Co (BMY) revenue declined by 100% year-over-year, from $48.3B to $47K in fiscal year 2025.

Is Bristol-Myers Squibb Co profitable?

Yes, Bristol-Myers Squibb Co (BMY) reported a net income of $7K in fiscal year 2025, with a net profit margin of 15.1%.

What is Bristol-Myers Squibb Co's earnings per share (EPS)?

Bristol-Myers Squibb Co (BMY) reported diluted earnings per share of $3.46 for fiscal year 2025. This represents a 178.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

How much debt does Bristol-Myers Squibb Co have?

As of fiscal year 2025, Bristol-Myers Squibb Co (BMY) had $10K in cash and equivalents against $43K in long-term debt.

What is Bristol-Myers Squibb Co's gross margin?

Bristol-Myers Squibb Co (BMY) had a gross margin of 70.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Bristol-Myers Squibb Co's net profit margin?

Bristol-Myers Squibb Co (BMY) had a net profit margin of 15.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Does Bristol-Myers Squibb Co pay dividends?

Yes, Bristol-Myers Squibb Co (BMY) paid $2.49 per share in dividends during fiscal year 2025.

What is Bristol-Myers Squibb Co's return on equity (ROE)?

Bristol-Myers Squibb Co (BMY) has a return on equity of 38.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Bristol-Myers Squibb Co's free cash flow?

Bristol-Myers Squibb Co (BMY) generated $13K in free cash flow during fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Bristol-Myers Squibb Co's operating cash flow?

Bristol-Myers Squibb Co (BMY) generated $14K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Bristol-Myers Squibb Co's total assets?

Bristol-Myers Squibb Co (BMY) had $90K in total assets as of fiscal year 2025, including both current and long-term assets.

What are Bristol-Myers Squibb Co's capital expenditures?

Bristol-Myers Squibb Co (BMY) invested $1K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Bristol-Myers Squibb Co spend on research and development?

Bristol-Myers Squibb Co (BMY) invested $10K in research and development during fiscal year 2025.

Does Bristol-Myers Squibb Co buy back shares?

Yes, Bristol-Myers Squibb Co (BMY) spent $5K on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Bristol-Myers Squibb Co have outstanding?

Bristol-Myers Squibb Co (BMY) had 2.04B shares outstanding as of fiscal year 2025.

What is Bristol-Myers Squibb Co's current ratio?

Bristol-Myers Squibb Co (BMY) had a current ratio of 1.26 as of fiscal year 2025, which is considered adequate.

What is Bristol-Myers Squibb Co's debt-to-equity ratio?

Bristol-Myers Squibb Co (BMY) had a debt-to-equity ratio of 2.32 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Bristol-Myers Squibb Co's return on assets (ROA)?

Bristol-Myers Squibb Co (BMY) had a return on assets of 7.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Bristol-Myers Squibb Co's Piotroski F-Score?

Bristol-Myers Squibb Co (BMY) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Bristol-Myers Squibb Co's earnings high quality?

Bristol-Myers Squibb Co (BMY) has an earnings quality ratio of 2.01x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Bristol-Myers Squibb Co?

Bristol-Myers Squibb Co (BMY) scores 51 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.